Vnitr Lek 2005, 51(3):276-278

Problematika hyperfosfatemie a jejích důsledků pro pacienty léčené dialýzou pro chronické selhání ledvin - editorial

S. Dusilová-Sulková
I. interní klinika 3. lékařské fakulty UK a FN Královské Vinohrady, Praha, přednosta prof. MUDr. Jiří Horák, CSc.

Received: July 4, 2004; Published: March 1, 2005  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dusilová-Sulková S. Problematika hyperfosfatemie a jejích důsledků pro pacienty léčené dialýzou pro chronické selhání ledvin - editorial. Vnitr Lek. 2005;51(3):276-278.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(Suppl 3): S1-201. Go to original source...
    2. Dunea G. Dialysis dementia: an epidemic that came and went. ASAIO J 2000; 47(3): 192-194. Go to original source... Go to PubMed...
    3. Malluche HH, Mawad H, Monier-Faugere MC. The importance of bone health in end-stage renal disease: out of frying pan, into the fire? Nephrol Dial Transplant 2004; 19(Suppl 1): 9-13. Go to original source... Go to PubMed...
    4. Chertow GM, Burke S, Raggi P et al. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62(1): 245-252. Go to original source... Go to PubMed...
    5. Locatelli F et al. The management of chronic renal insufficiency in the conservative phase. Nephrol Dial Transplant 2000; 15(10): 1529-1534. Go to original source... Go to PubMed...
    6. Rufino M et al. Is it possible to control hyperphosphataemia with diet, without inducing protein malnutrition? Nephrol Dial Transplant 1998; 13(Suppl 13): 65-67. Go to original source... Go to PubMed...
    7. Chen NX, O'Neil KD, Duan D et al. Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int 2002; 62(5): 1724-1731. Go to original source... Go to PubMed...
    8. Giachelli CA. Vascular calcification: in vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol 2003; 15(12): S300-S304. Go to original source... Go to PubMed...
    9. Gutzwiller JP, Schneditz D, Huber AR et al. Estimating phosphate removal in haemodialysis: an additional tool to quantify dialysis dose. Nephrol Dial Transplant 2002; 17(6): 1037-1044. Go to original source... Go to PubMed...
    10. McIntyre CW, Patel V, Taylor GS et al. A prospective study of combination therapy for hyperphosphataemia with calcum containing phosphate binders and sevelamer in hypercalcemic haemodialysis patients. Nephrol Dial Transplant 2002; 17(9): 1643-1648. Go to original source... Go to PubMed...
    11. Almirall J, Campistol JM, Torras A et al. Calcium carbonate as phosphate binder in dialysis. Lancet 1987; 330(8562): 799-800. Go to original source... Go to PubMed...
    12. D'Haese P, Spasovski GB, Sikole A et al. A multicenter study on the effects of lanthanum carbonate (Fosrenolr) and calcium carbonate of renal bone disease in dialysis patients. Kidney Int 2003; 85(Suppl): S73-S78. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.